Evidence map›Paper›PMID 35340824›Full record

ArticleInternational journal of nanomedicine2022

Antisense

Yuting Tian, Yue Zhang, Mengjiao Zhang, Xianchun Chen, Lei Lei, Tao Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Overexpression of ASFrontiers in cellular and infection microbiology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yuting Tian *State Key Laboratory of Oral Diseases, Department of Preventive Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.ORCID 0000-0002-2058-9735
Yue Zhang *State Key Laboratory of Oral Diseases, Department of Preventive Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Mengjiao ZhangWest China School of Pharmacy, Sichuan University, Chengdu, 610041, People's Republic of China.
Xianchun ChenCollege of Polymer Science and Engineering, Sichuan University, Chengdu, 610065, People's Republic of China.
Lei LeiState Key Laboratory of Oral Diseases, Department of Preventive Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.ORCID 0000-0002-0125-0904
Tao HuState Key Laboratory of Oral Diseases, Department of Preventive Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: VicR is the essential response regulator related to the synthesis of exopolysaccharide (EPS) - one of the main cariogenic factors of Methods: Aminated dendritic mesoporous silica nanoparticles (DMSNs-NH Results: DMSNs-NH Conclusion: DMSNs-NH

Indexed as

Dental CariesNanoparticlesBiofilmsHumansSilicon DioxideStreptococcus mutansSilicon Dioxidebiofilmcariogenicityexopolysaccharidesmesoporous silica nanoparticlesStreptococcus mutans

Identifiers

PMID35340824
PMCPMC8956320
OpenAlexW4226119903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.